The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a greater subst